fashion -WSS

fashion

author：hotspot 2025-09-27 19:37:46 - browse：7

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Senators start work on Medicare physician payment reform

focus

WSS

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

With fresh data, a dynamic duo powers Eli Lilly to new heights

Gilead might be held responsible for not developing a drug

A disappointing year of Humira biosimilars

What should King Charles tell the public about his cancer?

Biogen Alzheimer’s drug launch off to slow start

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

FDA approves Leqembi, a milestone in Alzheimer’s treatment

What does generative AI mean for health care? We asked experts

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Apple is now the first public company to be valued at $3 trillion

For Medicare Advantage, Democrats want stronger protections around AI

After affirmative action ruling, medical educators look to 'holistic review'

Private equity deals in Medicare Advantage declines

Apple is now the first public company to be valued at $3 trillion

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

hotspot

BioAge raises $170M for combination therapy with Zepbound

Readout LOUD podcast: How biotech is using artificial intelligence

The PBM ad wars are taking over Washington, D.C.

North Korean leader's powerful sister says warplanes repelled US spy plane

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Private equity deals in Medicare Advantage declines

explore

focus

focus

entertainment